Premark Pharma announced today the completion of a licensing deal with Novartis. Both based in Switzerland, Premark Pharma secured the exclusive worldwide rights to develop and commercialize PMP20207, an ophthalmic ointment formulation, as a potential treatment for blepharitis.
Blepharitis is an inflammation of the eyelids. Blepharitis usually involves the part of the eyelid where the eyelashes grow and affect both eyelids. Commonly occurring when tiny oil glands located near the base of the eyelashes become clogged, it can frequently lead to irritated and red eyes. Several diseases and conditions can cause blepharitis.
A chronic condition that is difficult to treat, Blepharitis can be uncomfortable and unsightly. It usually doesn’t cause permanent damage—it is not contagious. The condition affects more than 10 million people visiting an ophthalmology clinic in the United States and a similar number is estimated in Europe.
What is PMP2207?
PMP2207 is a novel ocular formulation of an established and well-characterized anti-inflammatory medicine. Initially, development activities will be focused on blepharitis, a chronic inflammatory condition of the eyelids, eyelid margins, and ocular surface. There are currently no approved treatments for blepharitis, which is one of the most common reasons for a patient to consult an ophthalmologist.
Recent Clinical Results
The results of Phase 2, 12-week, randomized, double-blind study, generated clear evidence of a clinically meaningful treatment effect of PMP2207 in blepharitis. Compared to patients receiving the ointment vehicle, those treated with PMP2207 experienced a greater improvement in both the signs and symptoms of blepharitis, which was evident after only two weeks and was sustained throughout the 12 weeks of treatment.
Recent Clinical Results
Premark Pharma, based in Switzerland, is a privately owned, development-stage pharmaceutical company focused on the development and commercialization of topical treatments for inflammatory diseases of the skin, eye, mucosae and mucocutaneous surfaces. The management team includes experts in ophthalmic clinical practice, drug development, and strategic marketing and the lead investor is a consortium of US-based ophthalmologists. The company’s current priority is the development and commercialization of the first drug treatment for blepharitis and PMP2207 is the lead asset.